A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression

NCT02512237 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped Replace with a new trial

Conditions

Breast Neoplasms
Stomach Neoplasms

Interventions

DRUG: ARX788

Sponsor

Zhejiang Medicine Co., Ltd.

Collaborators

[object Object]